FDA Approvals, Digital Health Guidance, Conference Presentations, and Recognitions - Analyst Notes on Intercept Pharmaceuticals, Cigna, Baxter, Questcor and Mallinckrodt

NEW YORK, June 3, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Intercept Pharmaceuticals Inc. (NASDAQ: ICPT), Cigna Corporation (NYSE: CI), Baxter International Inc. (NYSE: BAX), Questcor Pharmaceuticals Inc. (NASDAQ: QCOR) and Mallinckrodt PLC (NYSE: MNK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3242-100free.

--
Intercept Pharmaceuticals Inc. Analyst Notes
On May 28, 2014, Intercept Pharmaceuticals Inc. (Intercept) announced that a Fast Track designation to obeticholic acid (OCA) for the treatment of primary biliary cirrhosis (PBC) patients has been granted by the U.S. Food and Drug Administration (FDA). Intercept stated that OCA is being developed to treat PBC patients who have an inadequate therapeutic response to, or those who couldn't tolerate, ursodiol - the only drug currently approved to treat the disease. The Company intends to complete its New Drug Application (NDA) of OCA for PBC in H1 2015, which will include data from the Phase 3 POISE trial along with two randomized Phase 2 trials that met their primary endpoints with high statistical significance. The full analyst notes on Intercept Pharmaceuticals are available to download free of charge at:

http://www.analystsreview.com/Jun-03-2014/ICPT/report.pdf

--
Cigna Corporation Analyst Notes
On May 22, 2014, Cigna Corporation (Cigna), together with Samsung Electronics Co. Ltd. (Samsung), announced that they are delivering the next generation of smart health coaching service, the Coach by Cigna, as part of S Health on Samsung Galaxy S5. According to Cigna, the new digital health guidance system is developed to help the Galaxy S5 users worldwide make better health a habit. S Health provides easy-to-use features that help users collect and integrate health information from their smartphones and new Samsung Gear devices, making health improvement an engaging part of everyday life. Cigna stated that Coach by Cigna is built on the experiences of the Company's health coaches, nutritionists, behavior specialists, and nurses, enabling it to offer digital health guidance with a personality, integrated within the S Health App. Eric Consolazio, Vice President of Consumer Information Technology, Cigna said, "By introducing Coach by Cigna to the Galaxy S5, we add a new dimension that can connect Samsung users around the world with our lifestyle and motivational expertise - anywhere, any time - and help them to meaningfully improve their personal health, well-being and lives." The full analyst notes on Cigna are available to download free of charge at:

http://www.analystsreview.com/Jun-03-2014/CI/report.pdf

--
Baxter International Inc. Analyst Notes
On May 27, 2014, Baxter International Inc. (Baxter) announced its participation at the Goldman Sachs 35th Annual Global Healthcare Conference on Tuesday, June 10, 2014 at 4:00 p.m. CT. Baxter stated that the live webcast of the presentation will be made accessible via the Company's website. A replay of the same will also be available until July 9, 2014. The full analyst notes on Baxter are available to download free of charge at:

http://www.analystsreview.com/Jun-03-2014/BAX/report.pdf

--
Questcor Pharmaceuticals Inc. Analyst Notes
On May 28, 2014, Questcor Pharmaceuticals Inc. (Questcor) announced that MS Views & News, Inc. (MS Views & News), a leading multiple sclerosis (MS) education, information, and advocacy organization, has awarded the Company with a "Recognition of Appreciation". The Company stated that President and Founder of MS Views & News, Stuart Schlossman, presented the award at a special reception held in conjunction with the Consortium of Multiple Sclerosis Centers Meeting & Exhibition at the Hilton Anatole, in Dallas, to Questcor's Vice Presidents Fran Olson and Darlene Romine who stood in behalf of the Company. Steve Cartt, Chief Operating Officer, Questcor said, "Questcor is honored to receive this recognition from MS Views & News. We are committed to serving the needs of MS patients, their families and the healthcare providers who care for them." Cartt added, "We look forward to continuing this important partnership in the future and furthering these important educational efforts for MS patients." The full analyst notes on Questcor are available to download free of charge at:

http://www.analystsreview.com/Jun-03-2014/QCOR/report.pdf

--
Mallinckrodt PLC Analyst Notes
On May 28, 2014, Mallinckrodt PLC (Mallinckrodt) announced that the U.S. Food and Drug Administration has accepted for filing the New Drug Application (NDA) for MNK-155, an investigational extended-release oral formulation of hydrocodone and acetaminophen, studied to manage moderate to moderately severe acute pain where using opioid analgesic is appropriate. According to the Company, the NDA submission was based on the positive results in a Phase 3 clinical trial, as well as a series of other clinical trials that evaluates pharmacokinetics, safety, and abuse liability of MNK-155. Mallinckrodt also stated that it recently received notice of allowance from the US Patent and Trademark Office in relation to composition claims toward unique design, formulation, pharmacokinetic, and release characteristics for MNK-155, making the Company believe that MNK-155 will have strong patent protection for its novel features. The full analyst notes on Mallinckrodt are available to download free of charge at:

http://www.analystsreview.com/Jun-03-2014/MNK/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED